Scancell (LON:SCLP) Stock Price Up 2.9% - Should You Buy?

Key Points

• Scancell Holdings plc experienced a stock price increase of 2.9%, resulting in a trading price of GBX 9.80 ($0.13), with a significantly low trading volume compared to its average.
• Insider Martin Diggle purchased 4.4 million shares at an average price of GBX 10, indicating significant insider confidence, as insiders now own 15.15% of the stock.
• Scancell's recent quarterly earnings reported an EPS of GBX (1.26), with forecasted earnings suggesting higher losses for the current fiscal year.

Scancell Holdings plc (LON:SCLP - Get Free Report)'s stock price rose 2.9% during mid-day trading on Wednesday . The stock traded as high as GBX 10.14 ($0.14) and last traded at GBX 9.80 ($0.13). Approximately 84,731 shares changed hands during trading, a decline of 92% from the average daily volume of 1,022,414 shares. The stock had previously closed at GBX 9.52 ($0.13).

Scancell Trading Up 2.9%

The company has a 50-day moving average price of GBX 10.03 and a 200-day moving average price of GBX 9.70. The firm has a market capitalization of £101.70 million, a price-to-earnings ratio of -471.15 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Scancell (LON:SCLP - Get Free Report) last released its quarterly earnings data on Thursday, September 11th. The company reported GBX (1.26) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

Insider Transactions at Scancell

In other news, insider Martin Diggle purchased 4,400,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were purchased at an average price of GBX 10 per share, for a total transaction of £440,000. In the last quarter, insiders purchased 7,652,236 shares of company stock worth $73,474,596. Company insiders own 15.15% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.